Europe Nucleic Acid Therapeutics Market

Growing concern about the use of nucleic acid therapies to address hereditary and chronic conditions is driving the market growth

The potential of nucleic acid medicines to cure hereditary and chronic illnesses is driving up demand for them. DNA and RNA are examples of nucleic acids, which are vital molecules that are crucial for controlling gene expression and protein synthesis in cells. Furthermore, market growth will be fueled by an increase in the number of nucleic acid therapies approved by the FDA or the European Medicines Agency (EMA). In recent years, there has been a notable surge in the approval and development of nucleic acid medicines, encompassing RNA and DNA-based treatments.

Technology advancements and our growing understanding of the genetic pathways behind many diseases are partly to blame for this. For example, Onpattro (patisiran), a small interfering RNA (siRNA) therapy, has been approved as a nucleic acid therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR). The FDA approved this treatment for RNA interference (RNAi) for the first time in 2018.

CDMOs can use a number of recent developments in manufacturing technology to increase productivity and cut expenses. The application of continuous manufacturing techniques is one such development. Instead of batch processing, which can be labor-intensive and need a large quantity of equipment, this method runs reactions in a continuous flow. Large amounts of starting materials and reagents are not required as frequently in continuous manufacturing, which also enables quicker processing times. The use of automated technologies for the purification and analysis of nucleic acids is another development.

Automation can help to lower expenses, boost efficiency, and decrease errors while also increasing accuracy. Additionally, by enhancing the scalability of nucleic acid manufacturing, these systems can let CDMOs generate vast amounts of nucleic acids for research or commercial purposes. Thus, driving the nucleic acid therapeutics market revenue.

The increasing incidence of genetic disorders across Europe is a primary driver for the Global Europe Nucleic Acid Therapeutics Market Industry. With an estimated 1 in 200 individuals affected by rare genetic diseases, the demand for innovative therapies is surging. This trend is expected to contribute significantly to the market's growth, with projections indicating a market value of 12.5 USD Billion in 2024. As healthcare systems prioritize personalized medicine, the focus on nucleic acid therapeutics is likely to intensify, fostering advancements in gene editing and RNA-based therapies.

The Europe nucleic acid therapeutics market area will grow at a significant rate due to the growing acceptance of innovative nucleic acid therapeutics and the accessibility of nucleic acid extraction technologies. The market expansion in this region is at its pinnacle and is anticipated to stay that way for the duration of the projected period because all favorable variables are present. Additionally, the growing investments in the healthcare industry have pushed research into the treatment of numerous illnesses and disorders.

Furthermore, this area holds the largest share of the European nucleic acid therapies market due to the presence of multiple startups and established companies, as well as FDA approvals.

Figure 2: EUROPE NUCLEIC ACID THERAPEUTICS MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the nucleic acid therapeutics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, nucleic acid therapeutics industry must offer cost-effective items.